Related references
Note: Only part of the references are listed.Cannabidiol prevents disruptions in sensorimotor gating induced by psychotomimetic drugs that last for 24-h with probable involvement of epigenetic changes in the ventral striatum
Joao F. C. Pedrazzi et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2021)
Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors
Naielly Rodrigues da Silva et al.
PHARMACOLOGICAL RESEARCH (2020)
Dysregulation of Midbrain Dopamine System and the Pathophysiology of Schizophrenia
Susan F. Sonnenschein et al.
FRONTIERS IN PSYCHIATRY (2020)
Behavioral effects of psychostimulants in mutant mice with cell-type specific deletion of CB2 cannabinoid receptors in dopamine neurons
Ana Canseco-Alba et al.
BEHAVIOURAL BRAIN RESEARCH (2019)
Mechanisms of cannabinoid CB2 receptor-mediated reduction of dopamine neuronal excitability in mouse ventral tegmental area
Zegang Ma et al.
EBIOMEDICINE (2019)
Association of Genetic Liability to Psychotic Experiences With Neuropsychotic Disorders and Traits
Sophie E. Legge et al.
JAMA PSYCHIATRY (2019)
Role of the endocannabinoid system in drug addiction
Jorge Manzanares et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Sex, Hormones, and Genotype Interact To Influence Psychiatric Disease, Treatment, and Behavioral Research
Aarthi R. Gobinath et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2017)
Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia
Marc Fakhoury
MOLECULAR NEUROBIOLOGY (2017)
The Impact of CB2 Receptor Ligands on the MK-801-Induced Hyperactivity in Mice
Marta Kruk-Slomka et al.
NEUROTOXICITY RESEARCH (2017)
Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative
Nicole R. Silva et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2017)
The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia
Oliver D. Howes et al.
BIOLOGICAL PSYCHIATRY (2017)
Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice
Hai-Ying Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Genetic association analysis of CNR1 and CNR2 polymorphisms with schizophrenia in a Korean population
Joon Seol Bae et al.
PSYCHIATRIC GENETICS (2014)
CB2 receptor agonism reverses MK-801-induced disruptions of prepulse inhibition in mice
Ramy Khella et al.
PSYCHOPHARMACOLOGY (2014)
Activation of the CB2 receptor system reverses amyloid-induced memory deficiency
Jiang Wu et al.
NEUROBIOLOGY OF AGING (2013)
Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice
Felipe V. Gomes et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2013)
Animal models for predicting the efficacy and side effects of antipsychotic drugs
Pedro H. Gobira et al.
REVISTA BRASILEIRA DE PSIQUIATRIA (2013)
Definition and description of schizophrenia in the DSM-5
Rajiv Tandon et al.
SCHIZOPHRENIA RESEARCH (2013)
A new cannabinoid CB2 receptor agonist HU-910 attenuates oxidative stress, inflammation and cell death associated with hepatic ischaemia/reperfusion injury
Bela Horvath et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Cannabinoid Type 2 Receptor Activation Downregulates Stroke-Induced Classic and Alternative Brain Macrophage/Microglial Activation Concomitant to Neuroprotection
Juan G. Zarruk et al.
STROKE (2012)
Brain cannabinoid CB2 receptors modulate cocaine's actions in mice
Zheng-Xiong Xi et al.
NATURE NEUROSCIENCE (2011)
The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects
Steven G. Kinsey et al.
NEUROPHARMACOLOGY (2011)
Deletion of CB2 Cannabinoid Receptor Induces Schizophrenia-Related Behaviors in Mice
Antonio Ortega-Alvaro et al.
NEUROPSYCHOPHARMACOLOGY (2011)
Brain Cannabinoid CB2 Receptor in Schizophrenia
Hiroki Ishiguro et al.
BIOLOGICAL PSYCHIATRY (2010)
Animal models of cognitive dysfunction and negative symptoms of schizophrenia: Focus on NMDA receptor antagonism
Joanna C. Neill et al.
PHARMACOLOGY & THERAPEUTICS (2010)
Assessment of Pharmacotherapy for Negative Symptoms of Schizophrenia
Elizabeth Hanson et al.
CURRENT PSYCHIATRY REPORTS (2010)
Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis
Dagmar Koethe et al.
BRITISH JOURNAL OF PSYCHIATRY (2009)
Prepulse inhibition of the startle response with chronic schizophrenia: A replication study
Masatsugu Moriwaki et al.
NEUROSCIENCE RESEARCH (2009)
Schizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality
John McGrath et al.
EPIDEMIOLOGIC REVIEWS (2008)
The CNR1 gene as a pharmacogenetic factor for antipsychotics rather than a susceptibility gene for schizophrenia
Nora Hamdani et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2008)
Models of schizophrenia in humans and animals based on inhibition of NMDA receptors
Vera Bubenikova-Valesova et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2008)
Brain Neuronal CB2 Cannabinoid Receptors in Drug Abuse and Depression: From Mice to Human Subjects
Emmanuel S. Onaivi et al.
PLOS ONE (2008)
Risperidone attenuates MK-801-induced hyperlocomotion in mice via the blockade of serotonin 5-HT2A/2C receptors
Yun-Ai Su et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2007)
The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice
Kim Fejgin et al.
PSYCHOPHARMACOLOGY (2007)
Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice
LE Long et al.
NEUROPSYCHOPHARMACOLOGY (2006)
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
JA Lieberman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol
K Hashimoto et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2005)
Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice
FA Moreira et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2005)
Transient N-methyl-D-aspartate receptor blockade in early development causes lasting cognitive deficits relevant to schizophrenia
MR Stefani et al.
BIOLOGICAL PSYCHIATRY (2005)
Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms
A Giuffrida et al.
NEUROPSYCHOPHARMACOLOGY (2004)
CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia
H Ujike et al.
MOLECULAR PSYCHIATRY (2002)
CB2 cannabinoid receptor-mediated peripheral antinociception
TP Malan et al.
PAIN (2001)
Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review
MA Geyer et al.
PSYCHOPHARMACOLOGY (2001)
Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon
NR Swerdlow et al.
BEHAVIOURAL PHARMACOLOGY (2000)
Impaired prepulse inhibition of acoustic startle in schizophrenia
A Parwani et al.
BIOLOGICAL PSYCHIATRY (2000)
Share Paper
